Supplier News: Olon, Roquette, Evotec & More
By

The latest from CDMOs, CMOs, and suppliers featuring Olon, Roquette, Evotec, Archimica, and Cellistic.

Chemicals/Chemical API Manufacturing
* Olon Adding High-Containment Production Line
* Archimica Starts Operations of $2-M API Expansion
Biologics Mfg
* Evotec Breaks Ground on Biologics Mfg Facility
* Cellistic Acquires Celyad’s Cell-Therapy Mfg Ops for $6 M
Formulation Development/Drug Product Manufacturing
* Roquette Completes Acquisition of Crest Cellulose


Chemicals/Chemical API Manufacturing

Olon Adding High-Containment Production Line
Olon, a Rodano (Milan), Italy-based CDMO of active pharmaceutical ingredients and intermediates, has begun an expansion of its Mahad, India manufacturing site, to install a new high-containment production line for containing and handling substances up to level OEB4 (up to 1µg/m3). The new line will be suitable for producing medium-volume batches.

This expansion is part of overall EUR 27-million ($27-million) that Olon is rolling out over 2022/2023 for expanding internal expertise and high-containment production capacity

Source: Olon


Archimica Starts Operations of $2-M API Expansion
Archimica, a Lodi, Italy-based CDMO of active pharmaceutical ingredients (APIs) and intermediates, has started operations of a EUR 2-million ($2-million) upgrade of its multi-purpose manufacturing capacity at its Lodi, Italy site.

The investment upgraded the company´s GMP capabilities and its overall 175 m3 reactor capacity for API and GMP building block custom process development and manufacturing projects from 10 kg to multiple tons through to hundreds of tons. The investment comprises a range of reactor and separation equipment capabilities.

Source: Archimica


Biologics Mfg

Evotec Breaks Ground on New Biologics Mfg Facility
Evotec, a Hamburg, Germany-based drug-discovery and development company, has begun construction of a new biomanufacturing facility in Toulouse, France.

The facility will use the J.POD modular continuous manufacturing setup, a modular biomanufacturing platform from Just – Evotec Biologics, a Evotec subsidiary and a biologics manufacturing platform company. This is the second facility using the J.POD platform. Just – Evotec Biologics opened the first facility using the platfom in Redmond, Washington in August 2021.

The facility is expected to be operational in the second half of 2024 and will create up to 150 new jobs on Evotec’s Campus Curie in Toulouse. 

Source: Evotec


Cellistic To Acquire Celyad’s Cell-Therapy Mfg Ops for $6 M
Cellistic, a Gosselies, Belgium CDMO of cell therapies, has agreed to acquire the manufacturing business unit of Celyad Oncology, a Mont-Saint-Guibert, Belgium-based bio/pharmaceutical company, for EUR 6 million ($6 million). The deal includes Celyad’s existing 11,000-square-foot facility in Mont-Saint-Guibert, Belgium, and related personnel of approximately 30.

Cellistic was launched in April 2022 and specializes in process development and manufacture of cell therapies based on human induced pluripotent stem cell (iPSC) technology. Cellistic says it plans to invest in the acquired facility for IPSC-based allogeneic cell therapies. Cellistic is a subsidiary of Ncardia, a Leiden, the Netherlands-based a contract provider of discovery and development services for iPSC-based products. The transaction is subject to customary conditions closing conditions and is expected to close in the fourth quarter of this year (2022).

Source: Cellistic


Formulation Development/Drug Product Manufacturing

Roquette Completes Acquisition of Crest Cellulose
Roquette, an excipient manufacturer, has completed its acquisition of Crest Cellulose, a Menakuru, Andhra Pradesh, India-based excipient manufacturer. Roquette had earlier acquired a majority stake in the company in 2018.

Source: Roquette